The treatment of<unk>  begins with the immediate cessation of the offending drug. For individuals developing<unk>  while taking multiple drugs, non-essential drugs should be discontinued and essential drugs should be replaced by chemically unrelated drugs that are used as alternatives to the discontinued drug(s). In cases of multiple drug intake, skin and/or in vitro testing may be of some use in identifying the offending drug. Beyond identifying and discontinuing the offending drug, individuals with mild symptoms may require no further treatment. Those troubled by more significant symptoms such as itching or fever may require antihistamines, topical corticosteroids, systemic corticosteroids, and/or antipyretics. Individuals suffering liver, lung, kidney, and/or severe skin complications may require high dosage systemic corticosteroids and organ-specific interventions. Skin infections, which may lead to sepsis, are potentially lethal complications of<unk> ; preventative methods and rapid treatment of such infections with appropriate antibiotics and, where needed, further supportive measures are critical in the treatment of this complication. Overall, however,<unk>  has a lethality of less than 5% with recent reports showing no fatalities. Typically, individuals with<unk>  have rapid rates of recovery even in when experiencing the cited complications.
Acute generalized exanthematous pustulosis
Streptococcal intertrigo
Impetigo herpetiformis
Acute cutaneous lupus erythematosus
Polymorphous light eruption
Keratolytic winter erythema
Shingles
Herpetic whitlow